Monday, June 27, 2022 4:06:38 PM
It's all just supposition that any agreement has even been discussed between Merck or anyone else and NWBO. It's very possible with Merck, in that they had an employee working with NWBO, but nothing is certain. Whatever was said or done was done under confidentiality agreements and even if all terms have been completely agreed to nothing would ever be said until the triggering events occurred. It could be far more than just achieving a certain stock price, things like submissions or approvals from the regulators could be part of what needs to be done as well.
As an IMGN investor I'm aware of a partnership they made many years ago that was delayed for well over a year when a refrigerator failed and all the product intended to be used in a Phase 1 trial was lost. IMGN originally contracted for it to be made, but when their contractors failed to do it, they finally did it themselves utilizing specific oriental mice to produce the MAB used in the conjugate drug. Ultimately the drug failed in Phase 1/2 trials. Drugs fail, it's a fact of life, but in the case of DCVax-L I believe it's quite clear that NWBO has succeeded based on the data we've seen to date. I believe that the full data will be substantially better than what we've seen as what we've seen hasn't matched what was said about the Top 100 patients in the trials.
Gary
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM